IceCure Medical jumps on U.S. ProSense install base growth after FDA clearance
IceCure Medical shares surged more than threefold late Wednesday morning on Nasdaq. The Israeli medical-device company said U.S. commercial adoption of its ProSense cryoablation system for breast cancer climbed sharply since it received FDA clearance last year. Cryoablation is a method that destroys tissue by freezing.